You are now leaving the Hypermunes.com Web site.

Links to external, non-Talecris Biotherapeutics Internet sites are provided as a courtesy; however, Talecris Biotherapeutics is not responsible for the availability or the content of such Web sites.

Please see our General Conditions of Use for more information.

OK     CANCEL
 

HyperTET® S/D [Tetanus Immune Globulin (Human)]
postexposure prophylaxis for tetanus

HyperTET® S/D Postexposure Prophylaxis for Tetanus

Tetanus Quick Facts

  • According to the Centers for Disease Control and Prevention (CDC), 40% of reported tetanus cases that were treated were in elderly persons aged 60 years or older1
  • 75.3% of immigrants (those not born in North America or Western Europe) who were treated in an emergency department had significantly lower quantities of tetanus antibodies2
  • Tetanus has a high fatality rate; during 1998-2000, the case-fatality rate for reported tetanus in the United States was 18%3
  • There are many ways of contracting tetanus besides a rusty nail—people can become infected with tetanus following surgery, burns, lacerations, abrasions, crush wounds, ear infections, dental infections, animal bites, abortion, pregnancy, body piercing and tattooing, and injection drug use. People can also get tetanus from splinters3

HyperTET S/D Quick Facts

  • HyperTET S/D is mercury (thimerosal) free and latex free4
  • HyperTET S/D has FDA labeling for removal of pathogenic prions that may cause TSEs* in humans
  • HyperTET S/D offers tamper-evident packaging and incorporates UltraSafe® Needle Guards to help protect the healthcare professional from needle-stick injuries4
  • HyperTET S/D contains high titers of tetanus antibodies for postexposure prophylaxis, providing rapid immune protection for up to 21 days4
  • HyperTET S/D offers convenient prefilled syringes for single-use IM injection only4

HyperTET S/D IMPORTANT SAFETY INFORMATION

HyperTET S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET S/D should be given only if the expected benefits outweigh the risks.

Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin, there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Tetanus Immune Globulin (Human) administration.

HyperTET S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Human TSEs (transmissible spongiform encephalopathies) are a group of neurodegenerative diseases related to mad cow disease.

References:

  1. Centers for Disease Control and Prevention. VPD surveillance manual, 4th edition, 2008.

  2. Talan DA, Abrahamian FM, Moran GJ, et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med. 2004;43:305-314.

  3. Immunization Action Coalition. Tetanus: questions and answers. http://www.immunize.org/catg.d/P4220.pdf. Accessed June 17, 2009.

  4. HyperTET S/D [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics; 2008.